Azacitidine Ä¡·á ÈÄ Æó ¼Õ»óÀÌ ¹ß»ýÇÑ °ñ¼öÇü¼ºÀÌ»óÁõÈıº 1¿¹
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 4È£ p.496 ~ p.500
±èȣö(Kim Ho-Cheol) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è»óÇü(Kim Sang-Hyung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¾ÈÁöȯ(Ahn Ji-Hwan) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±ÇÇý¹Ì(Kwon Hye-Mi) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖÁ¾ÇÑ(Choi Jong-Han) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÅÂÇü(Kim Tae-Hyung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÁ¦È¯(Lee Je-Hwan) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78- year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient¡¯s subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
Å°¿öµå
Myelodysplastic Syndrome, Azacitidine, Lung injury
KMID :
0882420140870040496
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)